Contact information
| matthew.snape@paediatrics.ox.ac.uk | |
| Tel | +44 (0) 1865 611400 |
Matthew Snape
BRC Consultant in Paediatrics and Vaccinology
- Honorary Senior Clinical Lecturer
Dr Matthew Snape, MBBS FRCPCH MD, is a Consultant in General Paediatrics and Vaccinology at the NIHR Oxford Biomedical Research Council and the Children’s Hospital Oxford, Oxford University Hospitals NHS Trust. He is also an Honorary Senior Clinical Lecturer at the Department of Paediatrics, University of Oxford, a Jenner Investigator and a fellow of St Cross College, Oxford.
Dr Snape graduated from the University of Melbourne in 1993 and completed his basic paediatric training at the Royal Children’s Hospital, Melbourne before continuing his training at St Mary’s Hospital, London. While working in the Paediatric Intensive Care Unit at St Mary’s hospital he became interested in the prevention of invasive meningococcal disease by immunisation, and on completion of his clinical training took up a post as a research fellow (later Clinical Lecturer) at the Oxford Vaccine Group, University of Oxford. While here he completed his post- graduate Doctor of Medicine (MD) degree, awarded by the University of Melbourne in 2009. He has been employed as a Consultant in General Paediatrics and Vaccinology by the Oxford University Hospitals NHS Trust since 2009. His principal areas of research relate to vaccines against meningococcal, pneumococcal, influenza and ebola disease, and prevention of disease through maternal immunisation.
Dr Snape was acknowledged as an NIHR Clinical Research Network ‘Leading Commercial Principal Investigator’ in 2015 by Dame Sally Davis, Chief Medical Office, and has published over 70 manuscripts relating to immunisation. He is also a member of the Meningitis Research Foundation's Medical Advisory Group.
Dr Snape is an Academic Training Programme Director for Oxford University Clinical Academic Graduate School (OUCAGS), with a particular focus on paediatric academic training.
-
Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].
Iro MA. et al, (2017), Vaccine, 35, 3279 - 3279
-
Memory B cell response to a PCV-13 booster in 3.5year old children primed with either PCV-7 or PCV-13.
Trück J. et al, (2017), Vaccine, 35, 2701 - 2708
-
Immune responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 year
Winslow RL. et al, (2017), Journal of the American Medical Association
-
Persistence of immune responses induced by Ebola virus vaccines.
Snape MD., (2017), The Lancet Global Health
-
High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.
O'Connor D. et al, (2017), Genome Med, 9, 11 - 11
-
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
Iro MA. et al, (2017), Vaccine, 35, 395 - 402
-
Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule.
Trück J. et al, (2016), Pediatr Infect Dis J
-
Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.
Pace D. et al, (2016), Vaccine, 34, 6350 - 6357
-
Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT.
Kent A. et al, (2016), Pediatrics, 138
-
Immunisation of the immunocompromised child.
Pinto MV. et al, (2016), J Infect, 72 Suppl, S13 - S22
-
The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.
Trück J. et al, (2016), The Pediatric infectious disease journal, 35, 787 - 793
-
Attitudes towards antenatal vaccination, Group B streptococcus and participation in clinical trials: Insights from focus groups and interviews of parents and healthcare professionals
McQuaid F. et al, (2016), Vaccine
-
Factors influencing women’s attitudes towards antenatal vaccines, Group B streptococcus and clinical trial participation in pregnancy: An on-line survey.
Snape MD. and voysey M., (2016), BMJ Open
-
Lymphocyte subpopulations in premature infants: an observational study.
Kent A. et al, (2016), Archives of disease in childhood. Fetal and neonatal edition
-
Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells.
Voysey M. et al, (2016), Vaccine, 34, 1657 - 1664
-
Immunogenicity and Reactogenicity of Novel Adenovirus Type 26 and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial
Snape MD. et al, (2016), Journal of the American Medical Association
-
Control of invasive meningococcal disease: is it achievable?
Marshall H. et al, (2016), Int J Evid Based Healthc, 14, 3 - 14
-
Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.
Lazarus R. et al, (2016), PLoS One, 11
-
Factors affecting the causality assessment of adverse events following immunisation in paediatric clinical trials: An online survey.
Voysey M. et al, (2015), Vaccine
-
Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study
Turner PJ. et al, (2015), BMJ, h6291 - h6291
-
Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age
Snape MD. et al, (2015), Pediatric Infectious Disease Journal
-
Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy.
Jeppesen CA. et al, (2015), J Infect, 71, 43 - 52
-
Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers.
McCullagh D. et al, (2015), BMJ Open, 5
-
Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.
McQuaid F. et al, (2015), CMAJ, 187, E215 - E223
-
Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial.
Hamaluba M. et al, (2015), Lancet Infect Dis, 15, 405 - 414
-
Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
Iro MA. et al, (2015), Lancet Infect Dis, 15, 172 - 180
-
Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination.
Thebault S. et al, (2015), PLoS One, 10
-
Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
Pace D. et al, (2015), BMJ (Clinical research ed.), 350, h1554 - h1554
-
A cross-sectional observational study of pneumococcal carriage in children, their parents, and older adults following the introduction of the 7-valent pneumococcal conjugate vaccine.
Hamaluba M. et al, (2015), Medicine (Baltimore), 94
-
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
Read RC. et al, (2014), Lancet, 384, 2123 - 2131
-
Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom.
Ramasamy MN. et al, (2014), Clin Vaccine Immunol, 21, 1164 - 1168
-
Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.
McQuaid F. et al, (2014), Pediatr Infect Dis J, 33, 760 - 766
-
Attitudes towards vaccination against group B streptococcus in pregnancy.
McQuaid F. et al, (2014), Arch Dis Child, 99, 700 - 701
-
Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine
O'Connor D. et al, (2014), Vaccine, 32, 3424 - 3430
-
Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine.
O'Connor D. et al, (2014), Vaccine, 32, 3424 - 3430
-
Will booster doses be required for serogroup B meningococcal vaccine?
McQuaid F. and Snape MD., (2014), Expert Rev Vaccines, 13, 313 - 315
-
Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action.
Barker CI. and Snape MD., (2014), Lancet Infect Dis, 14, 227 - 238
-
Pneumococcal serotype-specific antibodies persist through early childhood after infant immunization: follow-up from a randomized controlled trial.
Trück J. et al, (2014), PLoS One, 9
-
Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.
Khatami A. et al, (2014), PLoS One, 9
-
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial
Read RC. et al, (2014), The Lancet, 384, 2123 - 2131
-
Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.
Hoschler K. et al, (2014), Clin Infect Dis, 58, 181 - 187
-
Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
Snape MD. et al, (2013), CMAJ, 185, E715 - E724
-
Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.
Rodgers GL. et al, (2013), Vaccine, 31, 4765 - 4774
-
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.
Snape MD. et al, (2013), Pediatr Infect Dis J, 32, 1116 - 1121
-
Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
de Whalley PC. et al, (2013), Arch Dis Child, 98, 686 - 691
-
Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: A follow-on study to a randomized clinical trial
Snape MD. et al, (2013), Pediatric Infectious Disease Journal, 32, 1116 - 1121
-
The price of prevention: what now for immunisation against meningococcus B?
Moxon R. and Snape MD., (2013), Lancet, 382, 369 - 370
-
A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
Martin NG. and Snape MD., (2013), Expert Rev Vaccines, 12, 837 - 858
-
Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis serogroups A, C, y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom
Blanchard-Rohner G. et al, (2013), Pediatric Infectious Disease Journal, 32, 768 - 776
-
Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom.
Blanchard-Rohner G. et al, (2013), Pediatr Infect Dis J, 32, 768 - 776
-
Genetic material should be routinely collected in clinical vaccine trials--high consent rates can be achieved across all age groups.
Trück J. et al, (2013), Vaccine, 31, 2744 - 2748
-
UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure.
Yates TA. et al, (2013), Arch Dis Child, 98, 429 - 433
-
Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants.
Khatami A. et al, (2013), Pediatr Infect Dis J, 32, 675 - 681
-
The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of age.
Blanchard-Rohner G. et al, (2013), Vaccine, 31, 2441 - 2448
-
The beginning of the end for serogroup B meningococcus?
Snape MD. and Pollard AJ., (2013), Lancet, 381, 785 - 787
-
The beginning of the end for serogroup B meningococcus?
Snape MD. and Pollard AJ., (2013), The Lancet, 381, 785 - 787
-
Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action
Barker CIS. and Snape MD., (2013), The Lancet Infectious Diseases
-
Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
Blanchard-Rohner G. et al, (2012), Vaccine, 30, 4153 - 4159
-
T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine
Lambe T. et al, (2012), Pediatric Infectious Disease Journal, 31
-
T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine.
Lambe T. et al, (2012), Pediatr Infect Dis J, 31, e86 - e91
-
The challenge of post-implementation surveillance for novel meningococcal vaccines.
Snape MD. et al, (2012), Vaccine, 30 Suppl 2, B67 - B72
-
Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations
Khatami A. et al, (2012), Vaccine, 30, 2831 - 2838
-
Immunogenicity of polysaccharide and conjugate
quadrivalent meningococcal ACYW-135 vaccines in
healthy adult volunteers – a randomised clinical trial
Ramasamy MN. et al, (2012), Clinical Microbiology and Infection. Supplement, 18
-
Single nucleotide polymorphisms in the toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine
Moore CE. et al, (2012), Clinical and Vaccine Immunology, 19, 295 - 303
-
Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine.
Moore CE. et al, (2012), Clin Vaccine Immunol, 19, 295 - 303
-
H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study.
Walker WT. et al, (2012), Clin Infect Dis, 54, 661 - 669
-
Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
Gossger N. et al, (2012), JAMA, 307, 573 - 582
-
Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations
Khatami A. et al, (2012), Vaccine, 30, 2831 - 2838
-
Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study
Khatami A. et al, (2012), Pediatr Infect Dis J, 31, 1069 - 1073
-
Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.
Khatami A. et al, (2011), Clin Vaccine Immunol, 18, 2038 - 2042
-
A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.
de Whalley P. et al, (2011), Health Technol Assess, 15, v - 128
-
Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine
De Whalley PCS. et al, (2011), Pediatric Infectious Disease Journal, 30
-
Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
de Whalley PC. et al, (2011), Pediatr Infect Dis J, 30, e203 - e208
-
Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.
Andrews NJ. et al, (2011), Vaccine, 29, 7913 - 7919
-
Fine with five? Shorter antibiotic courses for childhood meningitis.
Snape MD. and Kelly DF., (2011), Lancet, 377, 1809 - 1810
-
Relationships between reactogenicity and age, dose number and immunogenicity in 937 children receiving two doses of ASO3(B)-adjuvanted split virion or whole virus H1N1 influenza A 2009 pandemic vaccines
Walker W. et al, (2011), INFLUENZA AND OTHER RESPIRATORY VIRUSES, 5, 332 - 333
-
Immunisation of adolescents in the UK.
Kale AR. and Snape MD., (2011), Arch Dis Child, 96, 492 - 495
-
A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
Su EL. and Snape MD., (2011), Expert Rev Vaccines, 10, 575 - 588
-
Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.
Khatami A. et al, (2011), Pediatr Infect Dis J, 30, 197 - 202
-
Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
Andrews NJ. et al, (2011), Vaccine
-
A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children
de Whalley P. et al, (2011), Health Technology Assessment, 15
-
MEMORY B CELL RESPONSES FOLLOWING IMMUNISATION WITH POLYSACCHARIDE AND CONJUGATE QUADRIVALENT MENINGOCOCCAL ACYW135 VACCINES IN HEALTHY ADULT VOLUNTEERS
Maheshi R. et al, (2010), JOURNAL OF INFECTION, 61, 517 - 517
-
Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.
Snape MD. et al, (2010), Pediatr Infect Dis J, 29, e80 - e90
-
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
Findlow J. et al, (2010), Clin Infect Dis, 51, 1127 - 1137
-
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
Snape MD. et al, (2010), Pediatr Infect Dis J, 29, e71 - e79
-
Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
Waddington C. et al, (2010), Health Technol Assess, 14, 1 - 130
-
Safety and immunogenicity of AS03 <inf>B</inf> adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study
Waddington CS. et al, (2010), BMJ (Online), 340
-
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
Waddington CS. et al, (2010), BMJ, 340
-
Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans.
Blanchard-Rohner G. et al, (2009), Blood, 114, 4998 - 5002
-
Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.
Leroux-Roels I. et al, (2009), Vaccine, 27, 6918 - 6925
-
Future of flu vaccines. Expediting clinical trials in a pandemic.
Pollard AJ. et al, (2009), BMJ, 339
-
Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.
Kelly DF. et al, (2009), Immunology, 127, 134 - 143
-
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP. et al, (2009), Pediatr Infect Dis J, 28, 186 - 193
-
Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
Snape MD. et al, (2009), Pediatr Infect Dis J, 28, 92 - 97
-
A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
Pace D. et al, (2008), Arch Dis Child, 93, 963 - 970
-
Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.
Snape MD. et al, (2008), BMJ, 336, 1487 - 1491
-
The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.
Blanchard Rohner G. et al, (2008), J Immunol, 180, 2165 - 2173
-
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
Snape MD. et al, (2008), JAMA, 299, 173 - 184
-
A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.
Pace D. et al, (2007), Pediatr Infect Dis J, 26, 1057 - 1059
-
Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.
Snape MD. et al, (2006), Clin Infect Dis, 43, 1387 - 1394
-
African tick bite fever.
Snape MD. and Pollard AJ., (2006), Lancet Infect Dis, 6
-
No evidence for capsule replacement...and Wales - Authors' Reply
Snape M. and Pollard A., (2006), Lancet Infectious Diseases, 6, 617 - 618
-
No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply
Snape MD. and Pollard AJ., (2006), LANCET INFECTIOUS DISEASES, 6, 617 - 618
-
CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells
Kelly DF. et al, (2006), Blood, 108, 2642 - 2647
-
Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.
Snape MD. et al, (2005), Pediatr Infect Dis J, 24, 128 - 131
-
Meningococcal polysaccharide-protein conjugate vaccines.
Snape MD. and Pollard AJ., (2005), Lancet Infect Dis, 5, 21 - 30
-
Quadrivalent meningococcal polysaccharide and conjugate vaccines: Interim results of a clinical trial in adult volunteers
Ramasamy MN. et al, Journal of Infection, 61
-
Plasma cell and memory B cell responses following immunisation with polysaccharide and conjugate quadrivalent meningococcal ACYW135 vaccines in healthy adult volunteers.
Ramasamy MN. et al
-
An increase in Accident and Emergency presentations for Adverse Events Following Immunisation after introduction of the group B meningococcal vaccine : an observational study.
Nainani V. et al, Archives of Disease in Childhood
-
Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease
Pollard AJ. et al
Recent Publications
5-
Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].
Iro MA. et al, (2017), Vaccine, 35, 3279 - 3279
-
Memory B cell response to a PCV-13 booster in 3.5year old children primed with either PCV-7 or PCV-13.
Trück J. et al, (2017), Vaccine, 35, 2701 - 2708
-
Immune responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 year
Winslow RL. et al, (2017), Journal of the American Medical Association
-
Persistence of immune responses induced by Ebola virus vaccines.
Snape MD., (2017), The Lancet Global Health
-
High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.
O'Connor D. et al, (2017), Genome Med, 9, 11 - 11